Beyond the headline share price, if you are asking whether LeMaitre Vascular stock offers good value today, the answer depends on how you look at valuation and which metrics you trust most.

Recently, the stock closed at US$97.75, with the price up 0.5% over the past week, down 13.3% over the past month, and up 21.9% year to date and 21.2% over the past year, so recent moves may have shifted how investors view both upside and risk.

This article is part of ongoing coverage of LeMaitre Vascular, with the focus on valuation rather than short term headlines or earnings commentary, providing context that is intended to remain useful over time.

Simply Wall St assigns LeMaitre Vascular a value score of 2 out of 6. The rest of this article will compare what that means across different valuation approaches and then finish with a broader framework to help you judge valuation more effectively.

LeMaitre Vascular scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: LeMaitre Vascular Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return, giving an estimate of what the business might be worth in total right now.

For LeMaitre Vascular, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model built on cash flow projections. The latest twelve month free cash flow is about $79.2m. Analysts provide explicit forecasts for several years, and beyond that Simply Wall St extrapolates cash flows, with one example projection of $80.4m in 2030. Each of these future cash flows is discounted back to today and summed.

On this basis, the DCF model suggests an intrinsic value of about $66.48 per share. Compared with the recent share price of $97.75, this framework indicates the stock is about 47.0% more expensive than the DCF estimate, which points to a rich valuation on this metric alone.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests LeMaitre Vascular may be overvalued by 47.0%. Discover 49 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: LeMaitre Vascular Price vs Earnings

For a profitable company like LeMaitre Vascular, the P/E ratio is a straightforward way to connect what you pay for each share with the earnings that sit behind it, which many investors find intuitive when comparing stocks side by side.

What counts as a “normal” P/E will usually move around based on how quickly earnings are expected to grow and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk tends to point to a lower multiple.

LeMaitre Vascular currently trades on a P/E of 35.79x, compared with the Medical Equipment industry average of 24.53x and a peer group average of 51.99x. Simply Wall St’s Fair Ratio for the stock is 20.79x, which is a proprietary estimate of what the P/E could be given factors such as earnings growth, profit margins, industry, market cap and identified risks.

This Fair Ratio is more tailored than a simple comparison with peers or the broad industry because it adjusts for company-specific characteristics rather than assuming all stocks deserve similar multiples. With the current P/E of 35.79x sitting well above the Fair Ratio of 20.79x, the stock screens as expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your LeMaitre Vascular Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your story about LeMaitre Vascular to the numbers by tying your assumptions for future revenue, earnings and margins to a forecast, a fair value and then a clear comparison with the current share price. All of this is available in an accessible tool on the Community page that updates when new earnings, news or guidance arrive. One investor might build a Narrative around the higher analyst target of US$124.00 with expectations for stronger cash returns and operating leverage, while another might align more with the lower US$94.00 target and focus on risks like pricing power, regulatory hurdles or product concentration. Seeing those two fair values side by side against today’s price can help you decide whether the stock looks closer to your buy, hold or sell zone.

Do you think there's more to the story for LeMaitre Vascular? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.